MARY HNEICH: Open Payments
NPI 1669753810 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,333 in 203 payments from 13 companies in 2025. Trend: 2023 $3,682 · 2024 $3,431 · 2025 $4,333
Food & beverage: $4,118Education: $215
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 26 | $880 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 38 | $849 |
| Alkermes, Inc. | 23 | $516 |
| Otsuka America Pharmaceutical, Inc. | 26 | $448 |
| Teva Pharmaceuticals USA, Inc. | 17 | $432 |
| Vanda Pharmaceuticals Inc. | 13 | $332 |
| E.R. Squibb & Sons, L.L.C. | 29 | $313 |
| Lundbeck LLC | 13 | $211 |
| Axsome Therapeutics, Inc. | 6 | $125 |
| Janssen Pharmaceuticals, Inc | 5 | $113 |
Products named: INGREZZA, CAPLYTA, REXULTI, ARISTADA, FANAPT, COBENFY, UZEDY, ABILIFY ASIMTUFII.
Industry payments across AL — which companies pay providers there.
